Friday, August 28, 2026

Docket Roundup: Uber Assault Intake Sets the Filing Pace

Ride-share assault claims drove the day’s volume as Uber Technologies, Inc., Passenger Sexual Assault (3084) added 29 filings, 19 through Chaffin Luhana LLP and 7 through Peiffer Wolf, the heaviest concentrated intake on the board. Zantac Products Liability (2924) followed with 18 filings, all from Keller Postman LLC as original Eastern District of Pennsylvania complaints, not MDL tag-alongs; the JPML on Aug. 7 denied further transfers because common discovery is complete and the dismissed federal merits rulings remain on appeal. School-district complaints kept Social Media Adolescent Addiction Personal Injury Products Liability (3047) in that same 18-filing band, with Wagstaff & Cartmell LLP lodging five and Verhine Verhine PLLC four. Hair Relaxer Marketing, Sales Practices, and Products Liability (3060) added 12 matters, seven from Dicello Levitt LLP and three from Ashcraft Gerel LLP. Dicello Levitt LLP also supplied five of the eight Aqueous Film-Forming Foams Personal Injury Products Liability (2873) filings, with Napoli Shkolnik adding two. See the full filing feed and firm-level breakdowns here.

8th Circuit Leaves Roundup Settlement in Missouri Court

The 8th U.S. Circuit Court of Appeals on Aug. 27 dismissed an objector appeal seeking to move Bayer’s $7.25 billion Roundup class settlement into federal court, keeping the deal in Missouri state court. Objectors contended a state court could not implement a nationwide resolution of current and future Roundup claims. The dismissal leaves the Sept. 14 final-approval hearing as the controlling date for whether the class settlement is entered. Opponents must now present those objections in the Missouri proceeding, not through a federal-forum fight. The ruling does not approve the settlement or authorize payments; it fixes the court that will decide approval, remaining opt-out disputes, and any revised terms.

JPML Sets Sept. 24 Stimulator Consolidation Arguments

The Judicial Panel on Multidistrict Litigation will hear argument Sept. 24 in Chicago on petitions to centralize federal injury suits as Abbott Laboratories Spinal Cord Stimulator Products Liability (3194) and Nevro Corporation Spinal Cord Stimulator Products Liability (3195). JPML petitions for centralization remain pending in both, and the Panel has not selected a transferee court. The hearing will not reopen Boston Scientific Corporation Spinal Cord Stimulator Products Liability (3181), already before Judge Josephine L. Staton in the Central District of California. A grant would pull Abbott and Nevro pretrial proceedings, discovery, and bellwether selection into two additional centralized tracks. A denial would leave those cases in their transferor districts, forcing overlapping device-defect theories to be litigated court by court.